More is better: combination therapies for myelodysplastic syndromes.

[1]  M. Sekeres,et al.  How we treat higher-risk myelodysplastic syndromes. , 2014, Blood.

[2]  R. Bejar.  Prognostic models in myelodysplastic syndromes. , 2013, Hematology. American Society of Hematology. Education Program.

[3]  V. Najfeld,et al.  A Phase II Trial Of Epigenetic Modulators Vorinostat In Combination With Azacitidine (azaC) In Patients With The Myelodysplastic Syndrome (MDS): Initial Results Of Study 6898 Of The New York Cancer Consortium , 2013 .

[4]  Z. Estrov,et al.  A Phase II Study Of The Combination Of Azacitidine and Lenalidomide In Patients (pts) With Higher Risk Myelodysplastic Syndromes (MDS) , 2013 .

[5]  P. Venugopal,et al.  A Report On a Phase 2 Trial Of Combination Therapy With Lenalidomide and Azacitidine In Patients With Non-Del 5q, Low Risk MDS , 2013 .

[6]  R. Chao,et al.  Combination Therapy With Mocetinostat, An Oral, Spectrum-Selective Histone Deacetylase (HDAC) Inhibitor, and 5-Azaciditine: Indication Of Clinical Activity In MDS , 2013 .

[7]  Ji‐Hyun Lee,et al.  A Phase II Clinical Trial Of Lenalidomide and Prednisone In Low and Intermediate-1 IPSS Risk, Non-Del (5q) MDS Patients , 2013 .

[8]  A. Stamatoullas,et al.  A Phase I-II Study Of The Efficacy and Safety Of Lenalidomide (LEN) Combined To Azacitidine (AZA) In Higher Risk MDS and AML With Del 5q – A Study By The Groupe Francophone Des Myelodysplasies (GFM) , 2013 .

[9]  M. Voso,et al.  Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Mishra,et al.  Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes , 2013, American journal of hematology.

[11]  P. Fenaux,et al.  How we treat lower-risk myelodysplastic syndromes. , 2013, Blood.

[12]  K. Götze,et al.  Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study , 2013, Leukemia.

[13]  Gabriela Silva,et al.  Vorinostat Induces Apoptosis and Differentiation in Myeloid Malignancies: Genetic and Molecular Mechanisms , 2013, PloS one.

[14]  D. Neuberg,et al.  Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). , 2012, Leukemia research.

[15]  J. Maciejewski,et al.  Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. , 2012, Blood.

[16]  R. Larson,et al.  A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide , 2012, Journal of Hematology & Oncology.

[17]  L. Rushton,et al.  Myelodysplastic Syndrome and Benzene Exposure Among Petroleum Workers: An International Pooled Analysis , 2012, Journal of the National Cancer Institute.

[18]  E. Estey,et al.  Safety and Efficacy of Bendamustine and Idarubicin in Combination Therapy for Patients Age ≥50 with Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome – Results From a Phase I/II Adaptive Design Study. , 2012 .

[19]  H. Kantarjian,et al.  Very High Rates of Clinical and Cytogenetic Response with the Combination of the Histone Deacetylase Inhibitor Pracinostat (SB939) and 5-Azacitidine in High-Risk Myelodysplastic Syndrome , 2012 .

[20]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[21]  A. Stamatoullas,et al.  Bortezomib combined with low‐dose cytarabine in Intermediate‐2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM , 2012, British journal of haematology.

[22]  M. Konopleva,et al.  Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Scott E. Smith,et al.  Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS) , 2012, Journal of Hematology & Oncology.

[24]  Scott E. Smith,et al.  A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate‐1 risk myelodysplastic syndrome , 2012, Cancer.

[25]  Masao Tanaka,et al.  Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline. , 2012, Anticancer research.

[26]  M. Sekeres,et al.  Combination strategies in myelodysplastic syndromes , 2012, International Journal of Hematology.

[27]  John D. Roberts,et al.  Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis - One Year Update , 2011 .

[28]  A. Wei,et al.  Determination of the Maximum Tolerated Dose of Panobinostat in Combination with a 5-Day Schedule of Azacitidine in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: Planned Interim Analysis of a Phase Ib/II Study , 2011 .

[29]  F. Ali-Osman,et al.  Abstract B229: Novel ezatiostat analogues disrupt binding of GSTP1 to all three major MAP kinases (JNK, ERK and p38) and exhibit context-dependent antitumor activity. , 2011 .

[30]  M. Cazzola,et al.  A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. , 2011, Blood.

[31]  J. Liesveld,et al.  Proteasome Inhibition in Myelodysplastic Syndromes and Acute Myelogenous Leukemia Cell Lines , 2011, Cancer Investigation.

[32]  M. Ocker,et al.  Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: “To Be or Not to Be Acetylated”? , 2011, Journal of biomedicine & biotechnology.

[33]  B. Quesnel,et al.  Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias , 2011, Leukemia.

[34]  U. Germing,et al.  Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid , 2011, Clinical Epigenetics.

[35]  F. Mandelli,et al.  Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes. , 2011, Leukemia research.

[36]  Li Ding,et al.  Recurrent DNMT3A Mutations in Patients with Myelodysplastic Syndromes , 2011, Leukemia.

[37]  J. Maciejewski,et al.  A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia , 2011, Cancer.

[38]  Benjamin L Ebert,et al.  Unraveling the molecular pathophysiology of myelodysplastic syndromes. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  A. Stamatoullas,et al.  Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. , 2011, Blood.

[40]  J. Maciejewski,et al.  Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher‐risk myelodysplastic syndromes , 2011, American journal of hematology.

[41]  J. Gabrilove,et al.  Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905 , 2010 .

[42]  H. Dombret,et al.  Lenalidomide (LEN) Combined To Intensive Chemotherapy (IC) In AML and Higher Risk MDS With Del 5q. Results Of a Phase I/II Study Of The Groupe Francophone Des Myelodysplasies (GFM) , 2010 .

[43]  E. Laborde.  Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death , 2010, Cell Death and Differentiation.

[44]  R. Ganetzky,et al.  Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  H. Dombret,et al.  Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome , 2010, Oncotarget.

[46]  B. Storer,et al.  Anti‐thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study , 2010, British journal of haematology.

[47]  E. Estey,et al.  Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept , 2010, British journal of haematology.

[48]  D. Berry,et al.  DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  R. Larson,et al.  Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  J. Soulier,et al.  Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.

[51]  P. Greenberg,et al.  Efficacy and Safety of Romiplostim in Patients with Low or Intermediate-Risk Myelodysplastic Syndrome (MDS) Receiving Decitabine. , 2009 .

[52]  M. Konopleva,et al.  Phase 2 Study of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome- Outcome in Previously Untreated Patients. , 2009 .

[53]  D. Cella,et al.  Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). , 2009, Blood.

[54]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[55]  E. Galanis,et al.  Vorinostat in solid and hematologic malignancies , 2009, Journal of hematology & oncology.

[56]  Scott E. Smith,et al.  Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome. , 2009, Blood.

[57]  P. Hartge,et al.  Obesity, lifestyle factors, and risk of myelodysplastic syndromes in a large US cohort. , 2009, American journal of epidemiology.

[58]  Daniel Birnbaum,et al.  Mutations of polycomb‐associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia , 2009, British journal of haematology.

[59]  J. Hainsworth,et al.  Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[61]  C. O'keefe,et al.  Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. , 2009, Blood.

[62]  J. Gabrilove,et al.  A Phase I Trial of the Epigenetic Modulators Vorinostat, in Combination with Azacitidine (azaC) in Patients with the Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): A Study of the New York Cancer Consortium , 2008 .

[63]  M. Konopleva,et al.  Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome , 2008 .

[64]  P. Vyas,et al.  5 ' Azacitidine in Combination with Valproic Acid Induces Complete Remissions in Patients with Advanced Acute Myeloid Leukaemia but Does Not Eradicate Clonal Leukaemic Stem/Progenitor Cells. , 2008 .

[65]  J. Issa,et al.  Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System , 2008, Cancer.

[66]  M. Cazzola,et al.  Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  L. Malcovati.  Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. , 2007, Leukemia research.

[68]  H. Deeg,et al.  Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. , 2007, Experimental hematology.

[69]  Jorge Cortes,et al.  Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. , 2007, Blood.

[70]  R. Schneider-Stock,et al.  Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors. , 2007, IDrugs : the investigational drugs journal.

[71]  A. List.  Evolving applications of lenalidomide in the management of anemia in myelodysplastic syndromes. , 2006, Cancer control : journal of the Moffitt Cancer Center.

[72]  Michael Rytting,et al.  Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. , 2006, Blood.

[73]  P. Greenberg,et al.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. , 2006, The New England journal of medicine.

[74]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[75]  M. Grever,et al.  Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. , 2006, Cancer research.

[76]  John M Bennett,et al.  Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.

[77]  S. Baylin,et al.  DNA methylation and gene silencing in cancer , 2005, Nature Clinical Practice Oncology.

[78]  Hui Yang,et al.  Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid. , 2005, Leukemia research.

[79]  D. Higgs,et al.  Somatic point mutations in RUNX1/CBFA2/AML1 are common in high‐risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia , 2005, European journal of haematology.

[80]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  I. Dybedal,et al.  A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life , 2003, British journal of haematology.

[82]  H. Kantarjian,et al.  Differences in CD33 intensity between various myeloid neoplasms. , 2002, American journal of clinical pathology.

[83]  G. Demetri,et al.  Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy , 2002, Cancer.

[84]  S. Minucci,et al.  Methyltransferase Recruitment and DNA Hypermethylation of Target Promoters by an Oncogenic Transcription Factor , 2002, Science.

[85]  H. Deeg,et al.  Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: A pilot study , 2002, Leukemia.

[86]  F. Appelbaum,et al.  Antibody-targeted therapy for myeloid leukemia. , 1999, Seminars in hematology.

[87]  M. Pincus,et al.  Regulation of JNK signaling by GSTp , 1999, The EMBO journal.

[88]  J. Herman,et al.  Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer , 1999, Nature Genetics.

[89]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[90]  N. Young,et al.  Interferon-gamma and tumor necrosis factor-alpha suppress both early and late stages of hematopoiesis and induce programmed cell death. , 1995, Journal of cellular physiology.